Relevant bibliographies by topics / Bone transplant / Journal articles
To see the other types of publications on this topic, follow the link: Bone transplant.

Journal articles on the topic 'Bone transplant'

Author: Grafiati
Published: 4 June 2021
Last updated: 2 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Bone transplant.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Barrett, AJ, MM Horowitz, RC Ash, et al. "Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia." Blood 79, no. 11 (1992): 3067–70. http://dx.doi.org/10.1182/blood.v79.11.3067.3067.

Full text
Abstract:
Abstract Philadelphia chromosome (Ph1)-positive acute lymphoblastic leukemia (ALL) has a poor prognosis when treated with conventional chemotherapy. We analyzed the outcome of 67 HLA-identical sibling bone marrow transplants (BMTs) for Ph1-positive ALL reported to the International Bone Marrow Transplant Registry (IBMTR). Twenty-one of 67 (31%) transplant recipients survived in continuous complete remission more than 2 years after transplant. Two-year actuarial probabilities (95% confidence interval) of leukemia-free survival were 38% (23% to 55%) for 33 patients transplanted in first remissio
APA, Harvard, Vancouver, ISO, and other styles
2

Barrett, AJ, MM Horowitz, RC Ash, et al. "Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia." Blood 79, no. 11 (1992): 3067–70. http://dx.doi.org/10.1182/blood.v79.11.3067.bloodjournal79113067.

Full text
Abstract:
Philadelphia chromosome (Ph1)-positive acute lymphoblastic leukemia (ALL) has a poor prognosis when treated with conventional chemotherapy. We analyzed the outcome of 67 HLA-identical sibling bone marrow transplants (BMTs) for Ph1-positive ALL reported to the International Bone Marrow Transplant Registry (IBMTR). Twenty-one of 67 (31%) transplant recipients survived in continuous complete remission more than 2 years after transplant. Two-year actuarial probabilities (95% confidence interval) of leukemia-free survival were 38% (23% to 55%) for 33 patients transplanted in first remission, 41% (2
APA, Harvard, Vancouver, ISO, and other styles
3

Nilsson, Susan K., Mark S. Dooner, Heinz-Ulrich Weier, et al. "Cells Capable of Bone Production Engraft from Whole Bone Marrow Transplants in Nonablated Mice." Journal of Experimental Medicine 189, no. 4 (1999): 729–34. http://dx.doi.org/10.1084/jem.189.4.729.

Full text
Abstract:
Allogeneic and autologous marrow transplants are routinely used to correct a wide variety of diseases. In addition, autologous marrow transplants potentially provide opportune means of delivering genes in transfected, engrafting stem cells. However, relatively little is known about the mechanisms of engraftment in transplant recipients, especially in the nonablated setting and with regard to cells not of hemopoietic origin. In particular, this includes stromal cells and progenitors of the osteoblastic lineage. We have demonstrated for the first time that a whole bone marrow transplant contains
APA, Harvard, Vancouver, ISO, and other styles
4

Slayton, William B., Xiao-Miao Li, Steven M. Guthrie, Marda L. Jorgensen, John R. Wingard, and Edward W. Scott. "Donor-Derived Hematopoietic Stem Cells Repair the Bone Marrow Sinusoids Following Bone Marrow Transplant." Blood 106, no. 11 (2005): 1714. http://dx.doi.org/10.1182/blood.v106.11.1714.1714.

Full text
Abstract:
Abstract Marrow sinusoidal capillaries provide a niche for megakaryocyte progenitors and possibly hematopoietic stem cells. We sought to determine the fate of host sinusoidal capillaries during marrow transplant. We transplanted whole bone marrow, 2000 sorted Linneg Sca-1pos c-kitpos (SKL) hematopoietic stem and progenitor cells, or single SKL cells (along with rescue marrow) from male mice expressing green fluorescent protein into lethally irradiated female C57/BL6 hosts. We used green fluorescence and the presence of the Y-chromosome to identify donor-derived cells. Sinusoidal engraftment wa
APA, Harvard, Vancouver, ISO, and other styles
5

Storb, Rainer. "Bone Marrow Transplantation for Aplastic Anemia." Cell Transplantation 2, no. 5 (1993): 365–79. http://dx.doi.org/10.1177/096368979300200503.

Full text
Abstract:
The increased survival of aplastic anemia patients treated by human leukocyte antigens (HLA)-identical marrow transplants is due in part to a decrease in the incidence of graft rejection. The decrease in rejection, in turn, results from the more judicious use of transfusions before transplant, the removal of sensitizing white blood cells from transfusion products, and improvements in the immunosuppressive conditioning programs used to prepare patients for transplant. In regards to the latter, radiation-based programs have been effective, although a cydophosphamide/antithymocyte globulin progra
APA, Harvard, Vancouver, ISO, and other styles
6

Szer, Jeffrey. "Bone marrow transplant." Medical Journal of Australia 170, no. 6 (1999): 258. http://dx.doi.org/10.5694/j.1326-5377.1999.tb127745.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Joyce, Angela. "Bone marrow transplant." Paediatric Nursing 1, no. 6 (1989): 21–23. http://dx.doi.org/10.7748/paed.1.6.21.s21.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Gluckman, E., AD Auerbach, MM Horowitz, et al. "Bone marrow transplantation for Fanconi anemia." Blood 86, no. 7 (1995): 2856–62. http://dx.doi.org/10.1182/blood.v86.7.2856.2856.

Full text
Abstract:
Abstract Fanconi anemia is a genetic disorder associated with diverse congenital abnormalities, progressive bone marrow failure, and increased risk of leukemia and other cancers. Affected persons often die before 30 years of age. Bone marrow transplantation is an effective treatment, but there are few data regarding factors associated with transplant outcome. We analyzed outcomes of HLA-identical sibling (N = 151) or alternative related or unrelated donor (N = 48) bone marrow transplants for Fanconi anemia performed between 1978 and 1994 and reported to the International Bone Marrow Transplant
APA, Harvard, Vancouver, ISO, and other styles
9

Gluckman, E., AD Auerbach, MM Horowitz, et al. "Bone marrow transplantation for Fanconi anemia." Blood 86, no. 7 (1995): 2856–62. http://dx.doi.org/10.1182/blood.v86.7.2856.bloodjournal8672856.

Full text
Abstract:
Fanconi anemia is a genetic disorder associated with diverse congenital abnormalities, progressive bone marrow failure, and increased risk of leukemia and other cancers. Affected persons often die before 30 years of age. Bone marrow transplantation is an effective treatment, but there are few data regarding factors associated with transplant outcome. We analyzed outcomes of HLA-identical sibling (N = 151) or alternative related or unrelated donor (N = 48) bone marrow transplants for Fanconi anemia performed between 1978 and 1994 and reported to the International Bone Marrow Transplant Registry
APA, Harvard, Vancouver, ISO, and other styles
10

Johnston, Laura J., Diana Patterson, Ning Tang, Christine McMurdo, Laura Adams, and Susan Chang. "Redesigning care to lower episode costs in bone marrow transplantation." Journal of Clinical Oncology 35, no. 8_suppl (2017): 16. http://dx.doi.org/10.1200/jco.2017.35.8_suppl.16.

Full text
Abstract:
16 Background: Increased scrutiny over costs of cancer care has led to the introduction of episode-based payment by federal and commercial insurers. National average billed charges for autologous and allogeneic transplant episodes of care are approximately $375K and $925K, respectively. Through comprehensive analysis of claims data, we identified leading drivers of cost in BMT episodes (which span 30 days before transplant through 60-100 days post-transplant) and cost reduction opportunities. By redesigning care delivery, we can reduce post-transplant admissions and potentially improve the hea
APA, Harvard, Vancouver, ISO, and other styles
11

Goldman, JM, R. Szydlo, MM Horowitz, et al. "Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase [see comments]." Blood 82, no. 7 (1993): 2235–38. http://dx.doi.org/10.1182/blood.v82.7.2235.2235.

Full text
Abstract:
Abstract We analyzed the outcome of 450 HLA-identical sibling bone marrow transplants for chronic myelogenous leukemia (CML) in chronic phase performed between 1985 and 1990 and reported to the International Bone Marrow Transplant Registry (IBMTR). All patients received either hydroxyurea (n = 292) or busulfan (n = 158) to treat their CML before transplant. The median interval between diagnosis and transplant was 10 months (range, 1 to 191). Patients treated with hydroxyurea had a higher probability (95% confidence interval) of leukemia-free survival (LFS) at 3 years than those treated with bu
APA, Harvard, Vancouver, ISO, and other styles
12

Goldman, JM, R. Szydlo, MM Horowitz, et al. "Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase [see comments]." Blood 82, no. 7 (1993): 2235–38. http://dx.doi.org/10.1182/blood.v82.7.2235.bloodjournal8272235.

Full text
Abstract:
We analyzed the outcome of 450 HLA-identical sibling bone marrow transplants for chronic myelogenous leukemia (CML) in chronic phase performed between 1985 and 1990 and reported to the International Bone Marrow Transplant Registry (IBMTR). All patients received either hydroxyurea (n = 292) or busulfan (n = 158) to treat their CML before transplant. The median interval between diagnosis and transplant was 10 months (range, 1 to 191). Patients treated with hydroxyurea had a higher probability (95% confidence interval) of leukemia-free survival (LFS) at 3 years than those treated with busulfan (6
APA, Harvard, Vancouver, ISO, and other styles
13

Xue, Elisabetta, and Filippo Milano. "Are we underutilizing bone marrow and cord blood? Review of their role and potential in the era of cellular therapies." F1000Research 9 (January 17, 2020): 26. http://dx.doi.org/10.12688/f1000research.20605.1.

Full text
Abstract:
Since the first hematopoietic stem cell transplant, over a million transplants have been performed worldwide. In the last decade, the transplant field has witnessed a progressive decline in bone marrow and cord blood utilization and a parallel increase in peripheral blood as a source of stem cells. Herein, we review the use of bone marrow and cord blood in the hematopoietic stem cell transplant setting, and we describe the recent advances made in different medical fields using cells derived from cord blood and bone marrow.
APA, Harvard, Vancouver, ISO, and other styles
14

Gajewski, J. L., G. L. Phillips, K. A. Sobocinski, et al. "Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease." Journal of Clinical Oncology 14, no. 2 (1996): 572–78. http://dx.doi.org/10.1200/jco.1996.14.2.572.

Full text
Abstract:
PURPOSE To determine the outcome of HLA-identical sibling bone marrow transplants in advanced Hodgkin's disease. PATIENTS AND METHODS We reviewed the data on 100 consecutive patients with Hodgkin's disease who received HLA-identical sibling bone marrow transplants between April 1, 1982 and August 12, 1992, reported to the International Bone Marrow Transplant Registry (IBMTR). The median interval from diagnosis to transplant was 2.5 years (range, < 1 to 14). All had advanced disease. Eighty-nine of 100 patients were not in remission at the time of transplant. Fifty had pretransplant Karnofsk
APA, Harvard, Vancouver, ISO, and other styles
15

Lee, Traci J., and LeAnne D. Kennedy. "Tacrolimus: An Alternative for Graft-Versus-Host Disease Prevention." Annals of Pharmacotherapy 34, no. 3 (2000): 377–81. http://dx.doi.org/10.1345/aph.18417.

Full text
Abstract:
OBJECTIVE: To evaluate the efficacy of tacrolimus for prevention of graft-versus-host disease (GVHD) in patients receiving allogeneic bone marrow transplants. DATA SOURCES: Published literature was identified through MEDLINE (January 1990–December 1998) using the key words tacrolimus, FK506, graft-versus-host disease, and bone marrow transplant. DATA SYNTHESIS: GVHD associated with allogeneic bone marrow transplant is a serious life-threatening complication. An evaluation of studies using tacrolimus for prevention of GVHD was conducted. CONCLUSIONS: Tacrolimus is effective for the prevention o
APA, Harvard, Vancouver, ISO, and other styles
16

Horowitz, MM, D. Przepiorka, RE Champlin, et al. "Should HLA-identical sibling bone marrow transplants for leukemia be restricted to large centers? [see comments]." Blood 79, no. 10 (1992): 2771–74. http://dx.doi.org/10.1182/blood.v79.10.2771.2771.

Full text
Abstract:
Abstract There is substantial evidence that the volume of medical procedures in a hospital has an inverse relationship with mortality. We analyzed data for 1313 recipients of HLA-identical sibling bone marrow transplants for early leukemia (acute leukemia in first remission or chronic myelogenous leukemia in first chronic phase) to determine whether transplant outcome differed in small and large centers. Transplants were performed in 86 bone marrow transplant centers active between the years 1983 and 1988, which participated in the International Bone Marrow Transplant Registry. Twenty-one (24%
APA, Harvard, Vancouver, ISO, and other styles
17

Horowitz, MM, D. Przepiorka, RE Champlin, et al. "Should HLA-identical sibling bone marrow transplants for leukemia be restricted to large centers? [see comments]." Blood 79, no. 10 (1992): 2771–74. http://dx.doi.org/10.1182/blood.v79.10.2771.bloodjournal79102771.

Full text
Abstract:
There is substantial evidence that the volume of medical procedures in a hospital has an inverse relationship with mortality. We analyzed data for 1313 recipients of HLA-identical sibling bone marrow transplants for early leukemia (acute leukemia in first remission or chronic myelogenous leukemia in first chronic phase) to determine whether transplant outcome differed in small and large centers. Transplants were performed in 86 bone marrow transplant centers active between the years 1983 and 1988, which participated in the International Bone Marrow Transplant Registry. Twenty-one (24%) centers
APA, Harvard, Vancouver, ISO, and other styles
18

Ullah, Khalil, Tahir S. Shamsi, and Salman N. Adil. "Bone Marrow Transplant Activity - A Country Report from Pakistan." Blood 110, no. 11 (2007): 5038. http://dx.doi.org/10.1182/blood.v110.11.5038.5038.

Full text
Abstract:
Abstract Bone Marrow transplant activity started in 1999 in Pakistan when Bismillah Taqee Institute of Health Sciences & Blood Diseases Centre started functioning in the southern port city of Karachi, Pakistan. Two years later in year 2001 Armed Forces Bone Marrow Transplant Centre started functioning in the northern part of country, Rawalpindi, Pakistan. In 2004 another transplant centre, started in Aga Khan University Hospital, Karachi, Pakistan. Since the establishment of these transplant centers a total of 349 allogeneic transplants have been carried out for various hematological disor
APA, Harvard, Vancouver, ISO, and other styles
19

Bernauer, Wolfgang, and Alois Gratwohl. "Bone Marrow Transplant Retinopathy." American Journal of Ophthalmology 113, no. 5 (1992): 604. http://dx.doi.org/10.1016/s0002-9394(14)74751-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
20

Lopez, Pedro F., Paul Sternberg, Charles K. Dabbs, W. R. Vogler, Ian Crocker, and Neil S. Kalin. "Bone Marrow Transplant Retinopathy." American Journal of Ophthalmology 112, no. 6 (1991): 635–46. http://dx.doi.org/10.1016/s0002-9394(14)77269-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
21

Milone, Jorge H., Juan J. Napal, Javier A. Bordone, et al. "Second Neoplasm after Bone Marrow Transplant (BMT)." Blood 106, no. 11 (2005): 5404. http://dx.doi.org/10.1182/blood.v106.11.5404.5404.

Full text
Abstract:
Abstract Introduction: the second neoplasm, are pathologies described during the post transplant evolution, often associated to immunosuppression. The post transplant lymphoproliferative syndromes, habitually associated to viruses are the most frequent. The BMT is a procedure clearly different from the rest of the transplants, and this difference would also be observed on the incidence and type of tumor in its evolution. The incidence of second malignancies after BMT is low, and is related to the use of chemotherapy, particulary alkylating. agents radiotheraphy and immunosuppression. Objective
APA, Harvard, Vancouver, ISO, and other styles
22

Ballen, Karen, Kathleen A. Sobocinski, Mei-Jie Zhang, Mukta Arora, Mary M. Horowitz, and Sergio Giralt. "Outcome of Bone Marrow Transplantation for Myelofibrosis." Blood 106, no. 11 (2005): 170. http://dx.doi.org/10.1182/blood.v106.11.170.170.

Full text
Abstract:
Abstract Myelofibrosis is a myeloproliferative disorder characterized by splenomegaly, bone marrow fibrosis and immature white and red blood cells. Allogeneic transplantation is the only curative therapy. In this study, we analyzed the outcomes of 320 patients receiving allogeneic hematopoietic stem cell transplants for myelofibrosis between 1989 and 2002, using the databases of the Center for International Bone Marrow Transplant Research (CIBMTR), a research affiliation of the International Bone Marrow Transplant Registry (IBMTR) and the National Marrow Donor Program (NMDP). This is the large
APA, Harvard, Vancouver, ISO, and other styles
23

Simões, Belinda Pinto, Fabiano Pieroni, Thalita Costa, et al. "Allogenic bone narrow transplantation in sickle-cell diseases." Revista da Associação Médica Brasileira 62, suppl 1 (2016): 16–22. http://dx.doi.org/10.1590/1806-9282.62.suppl1.16.

Full text
Abstract:
SUMMARY Sickle-cell diseases are the most common inherited hemoglobinopathies worldwide. Improvement in survival has been seen in the last decades with the introduction of careful screening and prevention of complications and the introduction of hydroxyurea. Stem-cell transplantation is currently the only curative option for these patients and has been indicated for patients with neurological events, repeated vaso-occlusive crisis, any organ damage or presence of red blood cell antibodies. Related bone-marrow or cord-blood transplant has shown an overall survival of more than 90% with a diseas
APA, Harvard, Vancouver, ISO, and other styles
24

Peffault de Latour, Régis, Vincent Lévy, Tarik Asselah, et al. "Long-term outcome of hepatitis C infection after bone marrow transplantation." Blood 103, no. 5 (2004): 1618–24. http://dx.doi.org/10.1182/blood-2003-06-2145.

Full text
Abstract:
AbstractChronic hepatitis C is often asymptomatic, at least during the first decade following hematopoietic stem cell transplantation. Progression to advanced liver disease or cirrhosis in patients surviving more than 10 years is currently thought to be rare. Among 1078 patients who underwent an allogeneic transplantation between January 1973 and January 1995, 96 patients infected by hepatitis C virus (HCV) during the transplantation period were studied. Cumulative incidence and analysis of risk factors for cirrhosis were analyzed, and the rate and risk of cirrhosis in transplant recipients we
APA, Harvard, Vancouver, ISO, and other styles
25

Angham Ahmed Hasan, Munaf H. Zalzala, and Abbas Al-Temimi. "Studying Risk Factors Association with Osteoporosis in Post Kidney Transplantation Patients." International Journal of Research in Pharmaceutical Sciences 11, no. 1 (2020): 200–206. http://dx.doi.org/10.26452/ijrps.v11i1.1807.

Full text
Abstract:
Osteoporosis that associate with kidney transplantation is an important cause of ‎morbidity to ‎the patients that warranted extensive study about possible causes of ‎osteoporosis in order to ‎implement several steps to reduce this risk. The current work aimed to investigate possible association between post kidney ‎transplant ‎immunosuppression therapy type and developing the ‎osteoporosis and evaluate the bone mass by using dual X-ray absorptiometry (DXA) post-renalal transplant. A case-control, conducted in kidney transplant center – medical city complex for ‎one year period (‎from October ‎
APA, Harvard, Vancouver, ISO, and other styles
26

Manthey, N., M. H. Kirschner, A. Neriich, G. O. Hofmann, K. Hahn, and K. Tatsch. "3-Phase bone imaging and SPECT in the follow up of patients with allogenic vascularized knee joint transplants." Nuklearmedizin 40, no. 06 (2001): 187–92. http://dx.doi.org/10.1055/s-0038-1625759.

Full text
Abstract:
SummaryVascularized allotransplantation of knee joints under immunosuppression is a novel approach in orthopedic surgery. During the postoperative course immunosuppressive management depends on perfusion and viability of the graft. Aim: Evaluation of different diagnostic tools in regard to their usefulness and reliability to provide information about microvascularity and viability of vascularized knee joint allografts. Methods: Four patients with allogenic knee joint transplants were studied up to 26 months after transplantation with 3-phase bone scans and SPECT. The results were compared with
APA, Harvard, Vancouver, ISO, and other styles
27

Iyer, Subramania. "Vascularised composite allotransplants: Transplant of upper extremities and face." Indian Journal of Plastic Surgery 48, no. 02 (2015): 111–18. http://dx.doi.org/10.4103/0970-0358.163037.

Full text
Abstract:
ABSTRACTTransplantation of solid organs and bone marrow has become a highly acceptable and often the only available clinical solution in many situations. It has been practiced across the globe for quite a long time since the first kidney transplant in 1954. Transplantation of tissues other than these, which was termed composite tissue allotransplantation and currently as vascularised composite allotransplantation (VCA) is gaining acceptance as a solution for complex reconstructive problems. This involves the transfer of multiple types of tissue such as bone, muscle, nerve, skin and blood vesse
APA, Harvard, Vancouver, ISO, and other styles
28

Williams, Shelly, Amy Braden, Brahm Vasudev, Jeanne Palmer, and Eric Cohen. "Renal Transplantation for End-Stage Renal Disease Following Bone Marrow Transplantation: A 10-Year Outcomes Review." Blood 114, no. 22 (2009): 4294. http://dx.doi.org/10.1182/blood.v114.22.4294.4294.

Full text
Abstract:
Abstract Abstract 4294 Background The incidence of hematopoietic stem cell transplantations (HSCTs) in the US is increasing dramatically each year. Nephrotoxic agents used in these patients often lead to kidney injury that can be severe and progress to end-stage renal disease (ESRD) requiring long term dialysis or kidney transplant. Kidney transplantation is the best method of renal replacement therapy and maintenance immunosuppression is the mainstay to prevent graft rejection. Immune tolerance is of substantial interest because it obviates the need for long-term immunosuppression. Methods We
APA, Harvard, Vancouver, ISO, and other styles
29

Shuster, J. J., A. B. Cantor, N. McWilliams, et al. "The prognostic significance of autologous bone marrow transplant in advanced neuroblastoma." Journal of Clinical Oncology 9, no. 6 (1991): 1045–49. http://dx.doi.org/10.1200/jco.1991.9.6.1045.

Full text
Abstract:
This report provides strong evidence for conducting a controlled randomized clinical trial of autologous bone marrow transplantation versus conventional chemotherapy in childhood neuroblastoma, which is disseminated beyond the intracavity nodes, and which is diagnosed in children older than 12 months of age. On the basis of two Pediatric Oncology Group (POG) studies, one a surgery plus conventional chemotherapy study (POG 8441) and the other an elective autologous transplant pilot protocol (POG 8340), there was no significant prognostic benefit of switching in remission from the surgery plus c
APA, Harvard, Vancouver, ISO, and other styles
30

Nilsson, Susan K., Mark S. Dooner, Candi Y. Tiarks, Heinz-Ulrich Weier, and Peter J. Quesenberry. "Potential and Distribution of Transplanted Hematopoietic Stem Cells in a Nonablated Mouse Model." Blood 89, no. 11 (1997): 4013–20. http://dx.doi.org/10.1182/blood.v89.11.4013.

Full text
Abstract:
Abstract Increasingly, allogeneic and even more often autologous bone marrow transplants are being done to correct a wide variety of diseases. In addition, autologous marrow transplants potentially provide an opportune means of delivering genes in transfected, engrafting stem cells. However, despite its widespread clinical use and promising gene therapy applications, relatively little is known about the mechanisms of engraftment in marrow transplant recipients. This is especially so in the nonablated recipient setting. Our data show that purified lineage negative rhodamine 123/Hoechst 33342 du
APA, Harvard, Vancouver, ISO, and other styles
31

Stotler, Christy, Edward Copelan, Ronald Sobecks, et al. "Are Back-Up Bone Marrow Harvests of Value in Unrelated Donor Allogeneic Transplants?." Blood 110, no. 11 (2007): 5023. http://dx.doi.org/10.1182/blood.v110.11.5023.5023.

Full text
Abstract:
Abstract In June 2007 four members of the University of Michigan Cardiothoracic transplant team died in a plane crash while transporting organs to an expectant transplant recipient. Matched Unrelated Donor Stem Cell transplants (MUDs) require that patients receive the preparative regimen before the hematopoeitic stem cells are transported. Our transplant program performs a “back-up” autologous harvest prior to administration of the conditioning regimen for use if the donor graft fails to arrive or if graft failure occurs. However, this practice is not uniform and insurers sometimes balk at pay
APA, Harvard, Vancouver, ISO, and other styles
32

Jones, RJ, SJ Sharkis, P. Celano, OM Colvin, SD Rowley, and LL Sensenbrenner. "Progenitor cell assays predict hematopoietic reconstitution after syngeneic transplantation in mice." Blood 70, no. 4 (1987): 1186–92. http://dx.doi.org/10.1182/blood.v70.4.1186.1186.

Full text
Abstract:
Abstract Hematopoietic reconstitution following syngeneic bone marrow transplantation with graded doses of untreated and drug-treated bone marrow was studied in B6D2F1 mice. Granulocyte-macrophage colony- forming units (CFU-GM) and spleen colony-forming units (CFU-S) showed similar in vitro drug sensitivities. Both the speed of hematologic recovery and survival of mice transplanted with untreated or drug- treated bone marrow were directly related to the number of CFU-GM or CFU-S transplanted. Similar hematologic recovery was seen for untreated marrow transplants and treated transplants that ha
APA, Harvard, Vancouver, ISO, and other styles
33

Jones, RJ, SJ Sharkis, P. Celano, OM Colvin, SD Rowley, and LL Sensenbrenner. "Progenitor cell assays predict hematopoietic reconstitution after syngeneic transplantation in mice." Blood 70, no. 4 (1987): 1186–92. http://dx.doi.org/10.1182/blood.v70.4.1186.bloodjournal7041186.

Full text
Abstract:
Hematopoietic reconstitution following syngeneic bone marrow transplantation with graded doses of untreated and drug-treated bone marrow was studied in B6D2F1 mice. Granulocyte-macrophage colony- forming units (CFU-GM) and spleen colony-forming units (CFU-S) showed similar in vitro drug sensitivities. Both the speed of hematologic recovery and survival of mice transplanted with untreated or drug- treated bone marrow were directly related to the number of CFU-GM or CFU-S transplanted. Similar hematologic recovery was seen for untreated marrow transplants and treated transplants that had similar
APA, Harvard, Vancouver, ISO, and other styles
34

Tobias, J. H., T. J. Chambers, and A. Gallagher. "The effects of ovarian transplantation on bone loss in ovariectomized rats." Journal of Endocrinology 142, no. 1 (1994): 187–92. http://dx.doi.org/10.1677/joe.0.1420187.

Full text
Abstract:
Abstract Although hormone replacement therapy can prevent postmenopausal bone loss, it does not restore bone mass to normal in patients with established osteoporosis. This might reflect a failure to reproduce certain aspects of gonadal function. One method of investigating this possibility would be to examine the effect of ovarian transplantation on the skeleton of osteopaenic ovariectomized rats. However, ovarian transplantation may not fully restore ovarian function to normal, and it is not known whether transplanted ovaries reproduce the action of native ovaries on the skeleton. Therefore,
APA, Harvard, Vancouver, ISO, and other styles
35

Dunstan, CR, NM Somers, GW McCaughan, S. Strasser, and RA Evans. "Bone histology during post-liver transplant bone loss." Bone 13, no. 5 (1992): A10. http://dx.doi.org/10.1016/8756-3282(92)90494-h.

Full text
APA, Harvard, Vancouver, ISO, and other styles
36

Lothe, Pooja, Tiffany Pompa, Maneesh Jain, et al. "Comparative Cost Analysis of Therapy in Sickle Cell Anemia: Supportive Care Vs. Bone Marrow Transplant." Blood 126, no. 23 (2015): 4466. http://dx.doi.org/10.1182/blood.v126.23.4466.4466.

Full text
Abstract:
Abstract Objective: A comparative cost analysis of sickle cell admissions vs. stem cell transplants in sickle cell patients. Hypothesis: We believe the overall cost of a bone marrow transplant for a sickle cell patient will be less than that of a patient with multiple sickle cell admissions. Background: Sickle cell disease remains an increasing burden to the cost of health care and health care providers. The disease results in a variety of serious organ system complications that can lead to life-long disabilities and/or early death. Despite the advent of hydroxyurea, sickle cell admissions and
APA, Harvard, Vancouver, ISO, and other styles
37

Millichap, J. Gordon. "Bone Marrow Transplant in Adrenoleukodystrophy." Pediatric Neurology Briefs 11, no. 7 (1997): 53. http://dx.doi.org/10.15844/pedneurbriefs-11-7-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
38

Seppa, Nathan. "Marrow Transplant Fights Bone Disease." Science News 155, no. 10 (1999): 148. http://dx.doi.org/10.2307/4011216.

Full text
APA, Harvard, Vancouver, ISO, and other styles
39

LARMOUTH. "Decisions in bone marrow transplant." Molecular Immunology 35, no. 11-12 (1998): 806. http://dx.doi.org/10.1016/s0161-5890(98)90530-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
40

Ruiz-Argüelles, Guillermo J. "Whither the bone marrow transplant?" Hematology 15, no. 1 (2010): 1–3. http://dx.doi.org/10.1179/102453310x12583347009892.

Full text
APA, Harvard, Vancouver, ISO, and other styles
41

Agaoglu, Galip, Kevin A. Carnevale, James E. Zins, and Maria Siemionow. "Bilateral Vascularized Femoral Bone Transplant." Annals of Plastic Surgery 56, no. 6 (2006): 658–64. http://dx.doi.org/10.1097/01.sap.0000203985.41242.f8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
42

Weber, Melinda S. "Surviving Autologous Bone Marrow Transplant." American Journal of Nursing 96, no. 4 (1996): 16Q. http://dx.doi.org/10.1097/00000446-199604000-00012.

Full text
APA, Harvard, Vancouver, ISO, and other styles
43

Lopez, Pedro F., Paul Sternberg, Charles K. Dabbs, W. R. Vogler, Ian Crocker, and Neil S. Kalin. "Bone Marrow Transplant Retinopathy: Reply." American Journal of Ophthalmology 113, no. 5 (1992): 605. http://dx.doi.org/10.1016/s0002-9394(14)74752-x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
44

Miles, AI. "Bone marrow transplant and toxoplasmosis." Leukemia 13, no. 5 (1999): 824. http://dx.doi.org/10.1038/sj.leu.2401362.

Full text
APA, Harvard, Vancouver, ISO, and other styles
45

Wiley, Frances McKinney, and Karen Ulfig House. "Bone Marrow transplant in children." Seminars in Oncology Nursing 4, no. 1 (1988): 31–40. http://dx.doi.org/10.1016/0749-2081(88)90054-x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
46

Rosati, Piero, and Antonella Bergamo. "Allogenic Hair Transplant in a Bone Marrow Transplant Recipient." Dermatologic Surgery 25, no. 8 (1999): 664–65. http://dx.doi.org/10.1046/j.1524-4725.1999.99004.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
47

Reyes, Morayma, and Jeffrey S. Chamberlain. "Donor Origin of Multipotent Adult Progenitor Cells in Radiation Chimeras." Blood 106, no. 11 (2005): 1395. http://dx.doi.org/10.1182/blood.v106.11.1395.1395.

Full text
Abstract:
Abstract Multipotent Adult Progenitor Cells (MAPC) are bone marrow derived stem cells that can be extensively expanded in vitro and can differentiate in vivo and in vitro into cells of all three germinal layers: ectoderm, mesoderm, endoderm. The origin of MAPC within bone marrow (BM) is unknown. MAPC are believed to be derived from the BM stroma compartment as they are isolated within the adherent cell component. Numerous studies of bone marrow chimeras in human and mouse point to a host origin of bone marrow stromal cells, including mesenchymal stem cells. We report here that following syngen
APA, Harvard, Vancouver, ISO, and other styles
48

Caffarelli, Carla, Maria D. Tomai Pitinca, Mario Alessandri, et al. "Timing of Osteoporotic Vertebral Fractures in Lung and Heart Transplantation: A Longitudinal Study." Journal of Clinical Medicine 9, no. 9 (2020): 2941. http://dx.doi.org/10.3390/jcm9092941.

Full text
Abstract:
Bone loss and bone fractures are common complications after organ transplantation. Many factors contribute to the pathogenesis of transplant osteoporosis, such as bone disease preceding transplantation, immunosuppressive medications, and nutritional and lifestyle factors. This study aimed to assess the incidence of vertebral fractures before and after lung and heart transplantation. This longitudinal study analyzed 213 electronic medical records of patients who underwent lung transplantation (n = 128) and heart transplantation (n = 85) at Siena University Medical Center between January 2000 an
APA, Harvard, Vancouver, ISO, and other styles
49

Baronciani, Donatella, Ariane Boumendil, Arnaud Dalissier, et al. "Hematopoietic Cell Transplantation in Thalassemia and Sickle Cell Disease: Report from the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Registry: 2000-2017." Blood 132, Supplement 1 (2018): 168. http://dx.doi.org/10.1182/blood-2018-168.

Full text
Abstract:
Abstract INTRODUCTION: Allogeneic hematopoietic cell transplantation (HCT) is a diffuse curative option for transfusion dependent thalassemia (TDT) and sickle cell disease (SCD). To verify transplant activity, distribution, demography, policies and outcomes the Hemoglobinopathy Registry was established inside the European Group for Blood and Marrow Transplantation (EBMT). After a previous analysis limited to TDT for the 2000-2010 period data (BMT 2016; 51:536-41), we performed an updated report considering TDT and SCD patients transplanted in the last eighteen years (years 2000-2017). METHODS:
APA, Harvard, Vancouver, ISO, and other styles
50

Miles, A. M., M. S. Markell, N. Sumrani, J. Hong, and E. A. Friedman. "Severe hyperparathyroidism associated with prolonged hungry bone syndrome in a renal transplant recipient." Journal of the American Society of Nephrology 8, no. 10 (1997): 1626–31. http://dx.doi.org/10.1681/asn.v8101626.

Full text
Abstract:
Although widely believed to resolve within 6 to 12 months of successful renal transplantation, hyperparathyroidism may persist or develop after renal transplantation and eventually require parathyroidectomy. Avid calcium retention by demineralized bones (hungry bone syndrome) is well-recognized after parathyroidectomy and usually resolves after a few weeks. This report documents the case of a renal transplant recipient with persistent hyperparathyroidism who developed a pathological fracture of the pelvis and required parathyroidectomy 1 year after transplant and then manifested severe and pro
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the bibliographies on the topic 'Bone transplant' for other source types:
Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography